O & O Alpan, LLC

Our Mission: We bridge the art and science of medicine to provide evaluation and therapies that work for patients.

Our History: In 2005, Dr. Oral Alpan started O & O Alpan as a center for clinical trials. He soon became a leader in patient recruitment and his success allowed him to expand his own research interest, including therapies for Eosinophilic Esophagitis. The company expanded in 2010 to include Dr. Ozlem Goker-Alpan and clinical trials with novel therapies for Lysosomal Storage Diseases. O & O Alpan remains a leader not only in clinical research, but also patient centered care for individuals with a wide range of allergy, immunological, and genetic conditions.

Our Services: O & O Alpan offers Allergy/Immunology, Genetics, and Infusion clinics for both children and adults. All three clinics offer flexible schedules tailored to individual needs and weekend hours on alternating Saturdays and Sundays. O & O Alpan also maintains a unique flow-cytometry based diagnostic laboratory and immunological research facility and includes a full-fledged Clinical Research Center, which helps with the diagnosis of many diseases, both rare and common.

Our Priorities: O & O Alpan's goal is to provide the personalized care by examining the multifaceted and integrated system of the whole patient. We provide treatment and access to up and coming therapies that best fit our patients’ individual health concerns.

Our success: the accomplishments made here led to expending our research to additional therapeutic areas such as eosinophilic esophagitis. In April 2010 Lysosomal Disorders research and treatment unit was established with the joining of Dr. Ozlem Goker-Alpan who also took the role of President and CMO of O&O Alpan. Our success over the past 5 years has rewarded us “partnership status” with CRO’s such as Quintiles, This partnership brings O&O ALPAN priority access to multiple clinical trials offering new treatment options for patients. We also offer partnership with community physicians for training and ongoing collaborative support to maximize clinical trials performance.